Two anti-angiogenic TKI-PET tracers, [11C]axitinib and [11C]nintedanib: radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents

Tyrosine kinase inhibitors (TKIs) are very attractive targeted drugs, although a large portion of patients remains unresponsive. PET imaging with EGFR targeting TKIs ([11C]erlotinib and [18F]afatinib) showed promise in identifying treatment sensitive tumors. The aim of this study was to synthesize two anti-angiogenic TKI tracers, [11C]axitinib and [11C]nintedanib, and to evaluate their potential for PET.

Source: Nuclear Medicine and Biology - July 12, 2016 Category: Nuclear Medicine Authors: Paul Slobbe, Alex J. Poot, Rianne Haumann, Robert C. Schuit, Albert D. Windhorst, Guus A.M.S. van Dongen Source Type: research